Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price8.67 USD
Fair value13.79
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Distribution9.44-8.2% to today ✓
2026-09-17Read Markdown9.83-11.8% to today ✓
2026-08-18Read Distribution11.41-24.0% to today ✓
2026-07-02Read Markdown10.09-14.1% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
DENTSPLY SIRONA Inc. holds its Distribution at $8.67. Consolidating, no directional conviction, held for 42 days.
As held on the ledger · 2026-10-02
Phase
Distribution · caution
Quantitative state
Consolidating, no directional conviction, held for 42 days
Price at the screen
$8.67
Valuation
N/A trailing · 5.75 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.85
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
45.46%
Below 33%
Interest-bearing debt is 45.5% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
18.68%
Below 49%
Money owed to the company is 18.7% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
DENTSPLY SIRONA's business is in a permissible area, but its interest-bearing debt is about 45% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-10-02 screen. The gold marker is the market price at the same screen. A 59.0% margin of safety to the base estimate.
Third-party analyst targets: 15 covering, consensus Hold. The average target sits +61% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-02 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
When your dentist picks up new equipment or consumables, this company sits behind many of those tools. Yet revenue sits flat, margins have turned deeply negative at minus 17 percent, and return on equity has collapsed to minus 38 percent. The forward multiple looks cheap at 9.1 times, but zero growth and sustained losses make the headline valuation a warning rather than a bargain.
We pass because the business shows no operating momentum and the margin of safety sits slightly negative at the current price. Analysts sit on a hold rating with a median target near the last traded level, offering little support for improvement. Ethical checks clear, yet the financial record alone removes any case for ownership.
Risks centre on whether the losses reflect temporary cost pressures or a structural decline in demand for dental equipment. Currency moves and healthcare spending cycles could widen the hole further. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
XRAY trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Distribution · changed$9.44-4.0%Entry 6
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 4.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (15 analysts) rates it none, with a mean price target of $14.
2026-09-17Markdown · changed$9.83-13.8%Entry 5
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 13.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (15 analysts) rates it none, with a mean price target of $14.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 13.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (15 analysts) rates it none, with a mean price target of $14.
2026-07-18Markdown$10.09+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (15 analysts) rates it none, with a mean price target of $14.
2026-07-03Markdown$10.09+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markdown$10.09Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.